Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine‐based chemotherapy

Abstract

Acute myeloid leukemia (AML) is a type of clinically and biologically heterogeneous hematological malignancy. 1 The underlying biological characteristics are the key factors to determine the prognosis of AML patients. 2-3 With the development of next-generation sequencing (NGS) technology, numerous recurrent gene mutations have been identified in AML. 4-6 Currently, cytogenetic and molecular testing has been integrated to assess the risk stratification. 7-8

FLT3-ITD Mutation and FLT3 Ligand Plasma Level Were Not Associated with One-Year Survival of Indonesian Acute Myeloid Leukemia Patients

“…Compared to other studies, the median leukocyte in our cohort is much lower. 22,23,26 The median blast level of this study is similar to a study by Ni et al 23 Additionally, we did not detect any difference in leukocyte level and blast percentage between mutant and wildtype group. These findings are in concordance with two studies in Iran and Middle East but different from other studies from other countries including Japan, China, and Europe.…”

“…These findings are in concordance with two studies in Iran and Middle East but different from other studies from other countries including Japan, China, and Europe. 21,[27][28][29][30][31] For platelet level, the cohort in this study had higher median level than the study by Ni et al but similar with the study by Scholl et al 23,26 Based on higher hemoglobin level and lower leukocyte level, the cohort in his study may have better prognosis when compared with other AML studies. Level of FLT3 ligand plasma below 4.1 pg/mL were more common in FLT3-ITD mutant group in our study.…”

“…26 Meanwhile, another study by Ni et al had median of 6.9 (2.6-14.3). 23 Both of these studies had lower hemoglobin than our cohort. Nevertheless, the hemoglobin level is still low as there is reduced erythropoiesis caused by blast proliferation in the bone marrow due to AML.…”

“…In contrast, other recent studies involving FLT3 recruited more male patients. 22,23 The mean BMI of our cohort is within normal range (18.5-22.9) based on Asia-Pacific guidelines. 24 In contrast to another study which has 121 patients with BMI above 30 kg/m 2 , our cohort has less patients with obesity.…”

“…The median survival of our cohort was 6 months which is lower than median survival of studies by Ni et al and Niparuck et al with median of 9.7 months and 9 months respectively. 23,33 It is possible that better treatment in their studies caused longer median survival.…”